Semaglutide 0.25 mg Dose

Starting dose guide for GLP-1 therapy: what to expect in the first weeks

View Dose Overview
Important: 0.25 mg is a starter dose used for treatment initiation, not full therapeutic weight loss dosing.

What is Semaglutide 0.25 mg?

The 0.25 mg dose is the initial starting phase of Semaglutide therapy, designed to help the body adapt to GLP-1 receptor activation.

It is not intended for weight loss on its own but serves as a tolerance-building phase before gradual dose escalation.

Why Start at 0.25 mg?

  • Reduces gastrointestinal side effects
  • Helps the body adjust to appetite suppression
  • Prepares for therapeutic dosing (0.5 mg and higher)
  • Improves long-term treatment tolerance

What to Expect in Week 1–4

  • Mild appetite reduction
  • Possible nausea or bloating
  • No major weight loss expected yet
  • Gradual adaptation of digestive system

Continue Treatment Progression

After the 0.25 mg phase, dosing is typically increased under medical supervision.

View Titration Schedule

Next Dosing Steps

Start Semaglutide Treatment

Access treatment plans, dosing guidance, and provider options.

View Full Semaglutide Guide Cost & Availability

FAQ

Minimal weight loss is expected; this dose is mainly for adaptation.

Typically 4 weeks before increasing to 0.5 mg under medical supervision.

Yes, mild nausea is a common early side effect as the body adjusts.

Access Semaglutide Treatment Options

Compare providers, pricing, and availability of Semaglutide treatment plans.

Check Treatment Options
View Pricing Guide
Medical consultation may be required before starting treatment.

Semaglutide Dosage Hub